Daily non-political popular news in brief.

Novel molecules developed at UB can boost vaccine potency

02-05-2008 · EurekAlert!

Two novel proteins studied by a University at Buffalo professor of microbiology and immunology appear to have the potential to enhance the production of antibodies against a multitude of infectious agents.

Keywords: novel, molecules, developed, boost, vaccine, potency, molecule

« Previous | Next »

Similar news on "Novel molecules developed at UB can boost vaccine potency":

NRC team uses new Quantum Technology to control molecules
10-12-2006 · EurekAlert!
Researchers at the National Research Council Canada have developed a new Quantum Technology, described in the October 13 Web release of Science, which uses laser pulses to control quantum processes. Quantum technologies manipulate molecular scale behaviour for novel applications. The new method uses the electric field of the laser, rather than the usual absorption of light, to control molecules. This strong electric field puts forces on a reacting molecule, steering it towards a specific outcome.
Similar news · Read more »
Novel vaccine concept developed by scientists at the Wistar Institute
01-31-2008 · EurekAlert!
A new vaccine design strategy developed by scientists at the Wistar Institute could help to develop vaccines against diseases like AIDS and cervical cancer. The secret is using a herpes simplex protein called glycoprotein D to block a receptor molecule on antigen-presenting cells. Wistar scientists showed that vaccine vectors made by fusing glycoprotein D with genes from HIV and HPV antigens increase the immune system's response to those antigens in cell cultures and mice.
Similar news · Read more »
Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine
04-15-2007 · EurekAlert!
Experimental vaccines to help the immune system fight tumors have rarely been designed to directly stimulate helper T cells, one of the body's most critical immune responders, because of the difficult process required to isolate and clone antigens for vaccine development. Now, a new technique may allow scientists to create a melanoma vaccine able to stimulate helper T cells. The approach may also aid in the development of other vaccines against cancers or infectious diseases.
Similar news · Read more »
Clemson scientists shed light on molecules in living cells
08-21-2007 · EurekAlert!
Clemson University chemists have developed a method to dramatically improve the longevity of fluorescent nanoparticles that may someday help researchers track the motion of a single molecule as it travels through a living cell. The chemists are exploiting a process called "resonance energy transfer."
Similar news · Read more »
Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
11-28-2007 · EurekAlert!
Sirtris Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that findings in the journal Nature demonstrate that Sirtris has developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including type 2 diabetes, by targeting SIRT1, a gene that controls the aging process.
Similar news · Read more »
Selecting life: Scientists find new way to search for origin of life
11-09-2006 · EurekAlert!
Over the last half century, researchers have found that mineral surfaces may have played critical roles activating molecules that would become essential ingredients to life. Identifying which biomolecule/ mineral surface pairs, however, has stumped scientists for years because of countless possible combinations. Now a team of researchers, led by Robert Hazen of the Carnegie Institution's Geophysical Laboratory, has developed new protocols and procedures for adapting DNA microarray technology to rapidly identify promising molecule/mineral pairs.
Similar news · Read more »
Researchers demonstrate novel method for studying the DNA binding of small molecules
06-04-2007 · EurekAlert!
Northeastern University professor Mark C. Williams and colleague Ioana Vladescu have discovered a novel method for studying the DNA binding of small molecules with unprecedented accuracy. Their paper, titled "Quantifying force-dependent and zero-force DNA intercalation by single-molecule stretching," has been published in the May 2007 issue of the prestigious Nature Methods.
Similar news · Read more »
Biocapture surfaces produced for study of brain chemistry
12-13-2007 · EurekAlert!
A novel method has been developed for attaching small molecules, such as neurotransmitters, to surfaces, which then are used to capture large biomolecules. Researchers can make the technique applicable to a wide range of "bait" molecules including drugs, chemical warfare agents, and environmental pollutants. Ultimately, the researchers also hope to identify synthetic biomolecules that recognize neurotransmitters so that they can fabricate extremely small biosensors to study neurotransmission in the living brain.
Similar news · Read more »
Advance in understanding of blood pressure gene could lead to new treatments
02-04-2007 · EurekAlert!
Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
Similar news · Read more »
Harvard scientists partner to develop and distribute new tuberculosis vaccine
02-17-2007 · EurekAlert!
Bioengineers and public health researchers at Harvard University have developed a novel spraying method for delivering the most common tuberculosis (TB) vaccine, providing a new low-cost and scaleable technique that offers needle-free delivery and greater stability at room temperature than existing methods. The process could one day provide a better approach for vaccination against TB and help prevent the related spread of HIV/AIDS in the developing world.
Similar news · Read more »